> ## Content Index
> Fetch the complete content index at: https://www.healthdatacon.io/llms.txt
> Use this file to discover other available public pages before exploring further.

# A failed trial screen should lead to care, not the end of the relationship
- URL: https://www.healthdatacon.io/articles/pharma-trial-screening-continuing-care-bhosai-wieloch-ansari/
- Published: 2026-11-17T20:40:00.000Z
- Updated: 2026-11-19T05:10:58.000Z
- Description: Pluto Health, Sanofi and Takeda leaders argued for connecting screening, practical support and patient communication beyond a single protocol.
- Author: HDM Staff
- Tags: Patient Care, Americas, HLTH

Dr. Joy Bhosai challenged pharmaceutical companies to judge a clinical-trial relationship by what happens to people who do not qualify, rather than only by who enrolls. The Pluto Health founder and CEO described organizing health histories, identifying care gaps and arranging services at home as ways to make research outreach useful even when a particular study is not an option.

“I would ask that we think about the patient experience beyond a specific trial or a protocol,” Bhosai said. Her argument shifted the focus from recruitment efficiency to continuity: someone willing to engage with research may still need screening, information or treatment, regardless of the protocol’s inclusion criteria.

Bhosai joined Dr. Mattias Wieloch, Sanofi’s head of U.S. autoimmune type 1 diabetes, and Samer Ansari, Takeda’s head of commercial innovation and external experiences, for the November 17 [Pharma Townhall](https://hlth.com/events/usa/agenda/2026/fish-bowl-pharma-edition-1?ref=healthdatacon.io). Ellen Knapp, lead intelligence analyst at CB Insights, moderated, asking how an industry managing AI adoption, pipelines and commercialization can make its patient relationships more coherent.

## Make the next step possible

Bhosai separated two problems that are often grouped together as engagement. People may not know which screening or follow-up is relevant to them, and even those who know what to do may be unable to fit it into their lives. More education addresses the first problem; it does not automatically create time, transport or a convenient appointment.

“The most important part is making that next step accessible,” she said. She described accessibility in practical terms: something that fits a person’s schedule, can sometimes happen at home and does not require navigating another difficult clinic visit. Her own difficulty finding time for care, despite being a physician, illustrated the distance between knowing a recommendation and acting on it.

Pluto’s approach, as she described it, starts with understanding a person’s health history and gaps in care, then connecting them with a service that can address the gap. Examples included sending a phlebotomist or a screening kit to the home and providing clinical staff who can answer questions. Research opportunities can be considered alongside care, rather than making trial qualification the only useful result.

Those examples were a description of the company’s service model, not a comparative evaluation of its effects on enrollment or health outcomes. Their operational significance is the order of the work. The relationship begins with what the person needs and which resources can be mobilized, with a trial becoming one possible next step.

## Earlier detection needs an agreed pathway

Wieloch approached the same problem from earlier identification of autoimmune type 1 diabetes. He described a shift from responding to established disease toward finding signals of risk sooner. His challenge was to connect laboratory information, family understanding and a healthcare system prepared to explain and act on the result.

“You want to be empowered for your health. You don't want to be empowered for your disease,” Wieloch said. He argued that information should help a person remain well and make decisions, rather than simply add a new label. The practical work includes understanding what a family is ready to hear and how it can obtain follow-up.

He described fear and guilt as obstacles when parents consider screening their children, especially in families already affected by disease. A decision may change over time, he said, making awareness and repeated opportunities for discussion more useful than treating an initial refusal as permanent. He also pointed to psychologists and patient communities as potential sources of support.

“Healthcare will not take a decision for a family, but the responsibility is the empowerment,” Wieloch said. His account placed responsibility on organizations to explain options and establish a next step while leaving the family’s choice intact. More sensitive detection technology does not remove that communication requirement.

Wieloch also discussed partnerships and easier sample collection as ways to reduce access barriers. The wider proposal was to coordinate routine care, research opportunities and monitoring so a person is not stranded after learning about risk. The townhall did not present a new universal screening protocol or establish that one collection method is appropriate for every family.

## A patient journey crosses company boundaries

Ansari argued that pharmaceutical companies, hospitals and payers often examine the journey from their own institutional viewpoint. A patient experiences the combined sequence of medicines, providers, appointments and information demands. Improving one organization’s interface will not necessarily make that entire sequence easier to navigate.

“It has to be a collective, a cohesive effort,” Ansari said. He emphasized timely, relevant information that patients and caregivers can use, with support adapted to the condition and situation. A person receiving a late cancer diagnosis may be overwhelmed by information, while someone with a rare disease may be dealing with years of uncertainty.

He extended that reasoning to trial decisions, calling for thoughtful inclusion and exclusion criteria and an empathetic explanation when someone learns whether they qualify. The decision itself remains important, but so does how it is communicated. An unexplained rejection can leave a person with the same healthcare needs and less confidence about what to do next.

The discussion also complicated the idea that AI will simply replace pharmaceutical representatives. Ansari distinguished promotional engagement from the scientific exchange provided by medical science liaisons and said human trust remains important. Bhosai, speaking as a clinician, emphasized evidence and peer support; Wieloch said clinicians may arrive better informed while still wanting to discuss patient-specific questions.

The panel also differed on wearables in trials. Bhosai cautioned that the same measurement can describe people with different experiences, making context essential. Ansari stressed passive data collection, while Wieloch emphasized future possibilities. Their disagreement reinforced the need to connect a signal to a person’s circumstances before deciding what it means.

## Licenses alone do not redesign a service

In Knapp’s lightning round, the panel disagreed about giving every employee an AI license. Ansari called that approach overrated when separated from process change. “The change really comes from redesigning the workflows and the processes in a team,” he said, warning that multiple tools can increase costs without improving how people work together.

That disagreement gave the broader conversation a useful constraint. AI may help collect information, reduce administrative work and connect services, but the townhall’s most concrete proposals required decisions about ownership: who explains a result, arranges the next service and remains available after a trial screen fails. For Bhosai, the closing question was what an organization does for a person over time. The answer cannot end with enrollment.